668477-53-0 Usage
Uses
Used in Pharmaceutical Industry:
(S)-4-benzyl-3-[(2S,3R)-3-(4-benzyloxy-2-ethyl-phenyl)-2-ethoxy-3-hydroxy-propionyl]-oxazolidin-2-one is used as a potential candidate for drug design due to its complex molecular structure and chiral nature, which may offer novel therapeutic properties and targets for various medical conditions.
Used in Organic Synthesis:
In the field of organic chemistry, (S)-4-benzyl-3-[(2S,3R)-3-(4-benzyloxy-2-ethyl-phenyl)-2-ethoxy-3-hydroxy-propionyl]-oxazolidin-2-one serves as a valuable building block for the synthesis of other complex organic molecules, potentially leading to the development of new pharmaceuticals, agrochemicals, or advanced materials.
Check Digit Verification of cas no
The CAS Registry Mumber 668477-53-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,6,8,4,7 and 7 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 668477-53:
(8*6)+(7*6)+(6*8)+(5*4)+(4*7)+(3*7)+(2*5)+(1*3)=220
220 % 10 = 0
So 668477-53-0 is a valid CAS Registry Number.
668477-53-0Relevant academic research and scientific papers
SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS
-
Page/Page column 68, (2010/02/07)
The present invention relates to compounds of formula (I) wherein R1 to R8 and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.
CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS
-
Page 53, (2010/02/06)
The present invention relates to compounds of Formula (I), wherein R1 to R6 and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment and/
NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS
-
Page 79, (2010/02/06)
The present invention relates to compounds of formula (I) wherein Rl to R10, X, Y and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.
